Table 2.
Evolution of immune cells and cytokine mediators in human CSF after aSAH.
| Immune cell/cytokine | Acute (days 0–1) | Pre-VSP (days 2–4) | VSP (days 5–9) | Post-VSP peak (days 10 +) |
|---|---|---|---|---|
| CD45 + Hematopoietic cells | ↓↓↓ | ↑ | ↑↑ | ↑↑↑ |
| CD3-CD161 + NK cells | ↑↑ | ↓ | ↓↓ | ↓↓↓ |
| CD3 + T-cells | ↑ | ↑↑ | ↑↑↑ | ↓ |
| CD8 + CD161 + Tc17 cells | ↑↑↑↑ | ↓ | ↓↓ | ↓↓↓ |
| CD45dimCD11b + Microglia | ↑ | ↑↑ | ↑↑↑ | ↑↑↑↑ |
| VEGF | ↑↑ | ↓ | ↓↓ | ↑ |
| MMP-9 | ↑↑ | ↓ | ↓↓ | ↑ |
Highlighted in bold are the immune cell subpopulation with most significant count changes.
VSP cerebral vasospasm; MMP-9 matrix metalloproteinase-9; NK natural killer; VEGF vascular endothelial growth factor.